Your browser is no longer supported. Please, upgrade your browser.
AKBA Akebia Therapeutics, Inc. daily Stock Chart
AKBA [NASD]
Akebia Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.43 Insider Own0.90% Shs Outstand118.20M Perf Week8.12%
Market Cap755.30M Forward P/E- EPS next Y-1.55 Insider Trans16.14% Shs Float114.62M Perf Month93.05%
Income-245.20M PEG- EPS next Q-0.47 Inst Own72.90% Short Float9.43% Perf Quarter33.68%
Sales325.30M P/S2.32 EPS this Y-46.10% Inst Trans-1.81% Short Ratio8.77 Perf Half Y44.24%
Book/sh3.93 P/B1.63 EPS next Y23.60% ROA-28.00% Target Price14.59 Perf Year-26.47%
Cash/sh1.23 P/C5.19 EPS next 5Y- ROE-44.80% 52W Range2.99 - 10.45 Perf YTD15.55%
Dividend- P/FCF- EPS past 5Y8.10% ROI-23.00% 52W High-38.85% Beta1.76
Dividend %- Quick Ratio0.80 Sales past 5Y- Gross Margin72.70% 52W Low113.71% ATR0.48
Employees325 Current Ratio1.30 Sales Q/Q72.90% Oper. Margin-86.50% RSI (14)67.93 Volatility6.45% 11.29%
OptionableYes Debt/Eq0.00 EPS Q/Q-0.50% Profit Margin-75.40% Rel Volume1.01 Prev Close6.35
ShortableYes LT Debt/Eq0.00 EarningsNov 12 BMO Payout- Avg Volume1.23M Price6.39
Recom2.10 SMA2027.86% SMA5045.88% SMA20024.41% Volume1,248,287 Change0.63%
Nov-14-19Reiterated Needham Buy $18 → $15
Aug-06-19Reiterated H.C. Wainwright Buy $19 → $17
Jul-11-19Reiterated H.C. Wainwright Buy $23 → $21
May-02-19Initiated JP Morgan Overweight $12
Mar-20-19Initiated Citigroup Neutral $9
Sep-07-18Resumed Morgan Stanley Equal-Weight
Aug-10-18Reiterated Needham Buy $20 → $18
Jun-06-18Reiterated H.C. Wainwright Buy $24 → $22
Dec-19-17Initiated Piper Jaffray Overweight $26
Dec-07-17Initiated BTIG Research Buy $30
Sep-15-17Initiated RBC Capital Mkts Sector Perform $17
Jul-10-17Reiterated H.C. Wainwright Buy $25 → $24
Apr-27-17Reiterated Needham Buy $14 → $18
Apr-27-17Reiterated H.C. Wainwright Buy $18 → $21
Dec-27-16Reiterated H.C. Wainwright Buy $17 → $18
Dec-20-16Reiterated JMP Securities Mkt Outperform $16 → $19
Nov-15-16Initiated Aegis Capital Buy
Sep-29-16Initiated Brean Capital Buy
Mar-16-16Reiterated Needham Buy $18 → $14
Jan-21-16Initiated Credit Suisse Neutral
Dec-11-19 01:57PM  Did Hedge Funds Drop The Ball On Akebia Therapeutics Inc (AKBA) ? Insider Monkey
Dec-10-19 12:22PM  Seth Klarman Pares Paratek Pharmaceuticals Stake GuruFocus.com +7.91%
Dec-03-19 04:06PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +14.10%
Dec-02-19 08:57AM  Options Traders Expect Huge Moves in Akebia Therapeutics (AKBA) Stock Zacks -15.42%
05:09AM  Introducing Akebia Therapeutics (NASDAQ:AKBA), The Stock That Slid 52% In The Last Five Years Simply Wall St.
Nov-27-19 09:45AM  5 Strong Buy Biotech Stocks With More Than 80% Upside InvestorPlace +11.67%
Nov-26-19 12:26PM  Large Option Trader Betting On Biotech Stock Akebia Following Insider Buys Benzinga
Nov-21-19 08:00AM  Akebia Therapeutics to Present at Upcoming Investor Conferences Business Wire
Nov-20-19 05:28PM  Edited Transcript of AKBA earnings conference call or presentation 12-Nov-19 2:00pm GMT Thomson Reuters StreetEvents +5.03%
Nov-12-19 09:15AM  Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates Zacks -9.02%
07:57AM  Akebia Secures $100 Million Non-Dilutive Term Loan Financing; Reports Third Quarter 2019 Financial Results Business Wire
07:20AM  The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat Benzinga
Nov-09-19 12:15PM  Akebia Announces Positive 52-week Efficacy and Safety Data for Vadadustat from Two Pivotal Phase 3 Studies in Japanese Patients with Anemia Due to Chronic Kidney Disease Business Wire
Nov-05-19 10:33AM  Will Akebia Therapeutics (AKBA) Report Negative Earnings Next Week? What You Should Know Zacks
Nov-04-19 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Nov-01-19 09:18AM  Can Akebia Therapeutics (NASDAQ:AKBA) Afford To Invest In Growth? Simply Wall St.
Oct-30-19 09:30AM  Akebia Therapeutics Inc (AKBA) Is Burning These Hedge Funds Insider Monkey
Oct-28-19 08:00AM  Akebia Therapeutics to Report Third Quarter 2019 Financial Results and Discuss Recent Business Highlights Business Wire
Oct-24-19 08:00AM  Akebia Announces Nine Abstracts Accepted for Presentation at the American Society of Nephrology Kidney Week 2019 Annual Meeting Business Wire -6.52%
Oct-16-19 07:06AM  The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch Benzinga
Oct-15-19 04:46PM  Akebia Files Lawsuit Against CMS for 2018 Action Rescinding Medicare Part D Coverage of FDA-Approved Auryxia® for its Iron Deficiency Anemia Indication and Imposing a Prior Authorization Requirement for its Hyperphosphatemia Indication Business Wire
Oct-02-19 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
12:27PM  Should You Worry About Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) CEO Pay Cheque? Simply Wall St.
Sep-24-19 08:00AM  Akebia Therapeutics to Present at the 2019 Cantor Global Healthcare Conference Business Wire
Sep-11-19 10:16PM  Edited Transcript of AKBA earnings conference call or presentation 8-Aug-19 1:00pm GMT Thomson Reuters StreetEvents
Sep-04-19 05:15PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Sep-03-19 02:21PM  In expense-laden biotech industry, here are the Mass. startups most in need of cash American City Business Journals
Sep-02-19 03:41PM  How Does Akebia Therapeutics, Inc. (NASDAQ:AKBA) Affect Your Portfolio Volatility? Simply Wall St.
Aug-09-19 11:51PM  Akebia Therapeutics, Inc. (AKBA) Q2 2019 Earnings Call Transcript Motley Fool +5.76%
08:00AM  Akebia Therapeutics to Participate in Upcoming Investor Conferences Business Wire
Aug-08-19 09:25AM  Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates Zacks +13.93%
08:00AM  Akebia Therapeutics Reports Second Quarter 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights Business Wire
Aug-05-19 08:00AM  Akebia Therapeutics® Announces Settlement of Auryxia® Patent Litigation with Par Pharmaceutical Business Wire -6.82%
Aug-02-19 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire -7.97%
Aug-01-19 10:33AM  Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jul-26-19 08:27AM  What Type Of Shareholder Owns Akebia Therapeutics, Inc.'s (NASDAQ:AKBA)? Simply Wall St.
Jul-25-19 08:00AM  Akebia Therapeutics to Report Second Quarter 2019 Financial Results Business Wire
Jul-23-19 04:00AM  Akebia Therapeutics Announces Submission of Vadadustat New Drug Application in Japan for Anemia Due to Chronic Kidney Disease by Collaboration Partner, MTPC Business Wire +5.82%
Jul-11-19 08:00AM  Akebia Therapeutics CEO, John P. Butler, Elected Chair of Kidney Care Partners Business Wire
Jul-10-19 08:00AM  Akebia Therapeutics Announces Collaboration Partners Positive Top-line Results of Phase 3 Clinical Study of Riona® (ferric citrate hydrate) in Adult Patients with Iron Deficiency Anemia in Japan Business Wire
Jul-02-19 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jun-20-19 09:21AM  When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)? Simply Wall St.
Jun-19-19 09:32PM  Hedge Funds Are Dumping Akebia Therapeutics Inc (AKBA) Insider Monkey
Jun-17-19 05:30PM  Edited Transcript of AKBA earnings conference call or presentation 9-May-19 1:00pm GMT Thomson Reuters StreetEvents +8.05%
Jun-11-19 07:30AM  Akebia Therapeutics Launches AkebiaCares, an Enhanced Patient Access Program for People with Chronic Kidney Disease Business Wire
Jun-04-19 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
May-29-19 08:00AM  Akebia Therapeutics to Participate in Upcoming Investor Conferences Business Wire
May-09-19 02:44PM  Akebia Therapeutics, Inc. (AKBA) Q1 2019 Earnings Call Transcript Motley Fool
01:16PM  Heres What Hedge Funds Think About Akebia Therapeutics Inc (AKBA) Insider Monkey
08:10AM  Akebia Therapeutics: 1Q Earnings Snapshot Associated Press
08:00AM  Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments Business Wire
May-08-19 11:45AM  Seth Klarman Keeps Buying This Biotech Stock GuruFocus.com
May-02-19 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
10:32AM  Will Akebia Therapeutics (AKBA) Report Negative Earnings Next Week? What You Should Know Zacks
08:00AM  Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings Business Wire
Apr-30-19 08:00AM  Akebia Therapeutics to Report First Quarter 2019 Financial Results Business Wire
Apr-10-19 10:30AM  Akebia Expands Vadadustat Licensing Deal With Vifor Pharma Zacks
Apr-09-19 01:00AM  Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement Business Wire
01:00AM  Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement Business Wire
Apr-05-19 04:19PM  Akebia Therapeutics to Present at the 18th Annual Needham Healthcare Conference Business Wire
Apr-01-19 08:00AM  Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Creation for All Shareholders CNW Group
Mar-27-19 07:20AM  Consolidated Research: 2019 Summary Expectations for ADT, HudBay Minerals, Whirlpool, Akebia Therapeutics, Nevro, and MicroStrategy Fundamental Analysis, Key Performance Indications GlobeNewswire
Mar-26-19 05:48PM  Akebia Therapeutics Inc (AKBA) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Mar-21-19 02:52AM  Edited Transcript of AKBA earnings conference call or presentation 18-Mar-19 8:30pm GMT Thomson Reuters StreetEvents
Mar-19-19 01:11AM  Akebia Therapeutics (AKBA) Q4 2018 Earnings Conference Call Transcript Motley Fool
Mar-18-19 04:05PM  Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights Business Wire
Mar-12-19 04:35PM  Why Akebia Therapeutics, Momo, and Switch Jumped Today Motley Fool +10.35%
11:55AM  Why Akebia Therapeutics Is Soaring Today Motley Fool
07:47AM  The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug Benzinga
04:00AM  Akebia Therapeutics Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Vadadustat in Japanese Patients with Anemia Due to Chronic Kidney Disease Business Wire
Mar-11-19 10:30AM  Analysts Estimate Akebia Therapeutics (AKBA) to Report a Decline in Earnings: What to Look Out for Zacks
Mar-06-19 07:00AM  Akebia Therapeutics to Host Fourth Quarter and Full-Year 2018 Investor Update Call and Webcast Business Wire
Mar-04-19 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Feb-19-19 07:18AM  Akebia Therapeutics, Inc. (NASDAQ:AKBA) Is Trading At A 29.34% Discount Simply Wall St.
Feb-14-19 05:09PM  Seth Klarman Disculoses 4th-Quarter Stock Purchases GuruFocus.com
Feb-04-19 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +7.21%
07:50AM  Report: Developing Opportunities within T-Mobile US, Noble, Akebia Therapeutics, Vornado Realty Trust, Bio-Rad Laboratories, and Standex International Future Expectations, Projections Moving into 2019 GlobeNewswire
Jan-30-19 09:18AM  Akebia Therapeutics (AKBA) Upgraded to Buy: Here's What You Should Know Zacks +5.15%
Jan-18-19 09:17AM  What Did Akebia Therapeutics, Inc.s (NASDAQ:AKBA) CEO Take Home Last Year? Simply Wall St.
Jan-02-19 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
07:00AM  Akebia Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-16-18 11:36PM  Hedge Funds Are Crazy About Akebia Therapeutics Inc (AKBA) Insider Monkey
Dec-14-18 05:10PM  Seth Klarman Gains Stake in Akebia Therapeutics GuruFocus.com -12.20%
11:27AM  Abrams Capital Managements Return, AUM and Holdings Insider Monkey
Dec-13-18 04:30PM  Akebia Poised To Become 'Renal Powerhouse' With Keryx Merger, Raymond James Says Benzinga
10:55AM  Why Akebia Therapeutics Is Soaring Today Motley Fool
07:00AM  Akebia Therapeutics and Keryx Biopharmaceuticals Complete Merger, Creating Fully Integrated Renal Company Business Wire
Dec-11-18 12:00PM  Akebia Therapeutics Shareholders Approve Merger with Keryx Business Wire
Dec-03-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Nov-30-18 08:55AM  Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Akebia Shareholders Vote FOR Proposed Merger with Keryx Business Wire
08:55AM  Glass Lewis Recommends that Keryx Biopharmaceuticals Stockholders Vote FOR the Proposed Merger with Akebia Therapeutics GlobeNewswire
Nov-29-18 08:35AM  Report: Developing Opportunities within Teleflex, Anthem, Crown Castle International, MSCI, GCI Liberty, and Akebia Therapeutics Future Expectations, Projections Moving into 2018 GlobeNewswire
07:00AM  Leading Independent Proxy Advisory Firm ISS Recommends Akebia Shareholders Vote FOR Proposed Merger with Keryx Business Wire
07:00AM  ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote FOR the Proposed Merger with Akebia Therapeutics GlobeNewswire
Nov-21-18 01:41PM  What Kind Of Shareholders Own Akebia Therapeutics Inc (NASDAQ:AKBA)? Simply Wall St.
Nov-20-18 04:05PM  Akebia Therapeutics to Participate in Upcoming Investor Conferences Business Wire
Nov-16-18 08:08AM  The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal Benzinga
Nov-15-18 05:15PM  Akebia Therapeutics and Keryx Biopharmaceuticals Announce Chairperson for Combined Company Business Wire +5.74%
Nov-14-18 12:11PM  David Abrams Buys 3 Stocks in 3rd Quarter GuruFocus.com
Nov-13-18 04:05PM  Akebia Therapeutics Sends Letter to Shareholders Business Wire
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Burke Steven KeithSVP, Chief Medical OfficerNov 20Buy3.5827,00096,66037,000Nov 22 06:19 AM
Smith CynthiaDirectorNov 20Buy3.5215,00052,80028,700Nov 22 06:20 AM
GILMAN STEVEN CDirectorNov 20Buy3.435,80019,89429,731Nov 22 06:20 AM
Butler John P.CEO and PresidentNov 20Buy3.4450,000172,000887,732Nov 21 06:32 AM
ADAMS ADRIANDirectorNov 20Buy3.4150,000170,50063,700Nov 21 06:31 AM
Butler John P.CEO and PresidentJun 03Option Exercise0.47287,000134,890836,232Jun 05 04:05 PM